HOWL Reverse-Merges With Ambros to Take Neridronate Public

Werewolf Therapeutics (Nasdaq: HOWL) is handing its public listing to a chronic-pain startup. On August 21, Werewolf and Ambros Therapeutics announced an all-stock reverse merger that gives Ambros shareholders 71.7% of the combined company and refocuses it on neridronate, a bisphosphonate for Complex Regional Pain Syndrome Type 1 (CRPS-1) that is already approved in Italy but has no US clearance.

The merged company, valued at roughly $500 million, will operate as Ambros Therapeutics and trade on Nasdaq under the ticker AMBX. Existing Werewolf shareholders keep 6.8%, and investors in a concurrent, oversubscribed $150 million private placement take the remaining 21.5%. The PIPE was co-led by RA Capital Management and Janus Henderson Investors. HOWL closed at $0.43 on August 21 (Polygon), down about 4% on the news, with roughly 66 million shares changing hands. The deal is expected to close by the first quarter of 2027.

Neridronate is an aminobisphosphonate that has been administered to about 600,000 patients in Italy, where it is approved for CRPS-1 under the name Neridronato. The drug concentrates at the site of injury during the “warm phase” of the condition, which is why the trial targets patients with positive triple-phase bone scans. The FDA has granted it Breakthrough Therapy, Fast Track, and Orphan Drug designations, and the agency has signaled that a single successful registrational trial could support approval. CRPS-1, formerly called reflex sympathetic dystrophy, brings an estimated 65,000 new US cases each year and has no FDA-approved therapy.

The asset driving the deal is the CRPS-RISE Phase 3 trial, a triple-blind, placebo-controlled study restricted to warm-phase CRPS-1 patients with positive triple-phase bone scans. Topline data is expected in 2028, and Ambros says the PIPE funds the company through that readout and a planned NDA, with runway into the first half of 2029.

The risk is real. The 71.7/6.8 ownership split heavily dilutes legacy Werewolf holders. Neridronate is also a bisphosphonate, a class with crowded generic economics, and the entire thesis rests on one trial with a 2028 readout.

Ambros was co-founded by Vivek Ramaswamy, the biotech entrepreneur and former presidential candidate. The reverse merger is a capital lifeline: rather than run a traditional IPO, Ambros uses Werewolf’s Nasdaq listing to go public while the $150 million PIPE supplies the funding for a trial that began dosing patients in June.

This is the latest in a 2026 wave of reverse mergers, where cash-strapped public shells give late-stage private assets a listing without a traditional IPO. For a framework on evaluating these deals, see the guide to biotech IPOs and listings.

Source: Werewolf and Ambros Therapeutics merger press release

What It Means for the Trade

This is a single-asset binary dressed up as a $500 million company, and the structure tells you how to trade it. Legacy HOWL holders keep 6.8% of a company whose value is essentially one Phase 3 trial reading out in 2028 — which is why the stock fell rather than popped on merger news: the dilution math dwarfed any listing premium. The instrument that owns the upside is the PIPE (RA Capital and Janus Henderson at 21.5% of the company for $150 million), and an oversubscribed placement led by tier-one biotech specialists is a genuine quality signal.

The catalyst calendar is long and sparse: CRPS-RISE topline in 2028, a planned NDA, and a re-listing as AMBX on Nasdaq by Q1 2027. Between now and the readout there is little to trade on beyond enrollment pace updates. Note the FDA posture embedded in the designations: Breakthrough Therapy plus Fast Track plus Orphan, plus an agency signal that a single registrational trial could support approval — the most de-risked regulatory setup a Phase 3 pain asset can have, reflecting the fact that CRPS-1 has no approved therapy.

Mechanism and Market Context

The biology is a repurposing story rather than novel chemistry: neridronate is an aminobisphosphonate, a bone-targeting drug class best known for osteoporosis, with roughly 600,000 patients of Italian real-world exposure behind it. The thesis is that CRPS-1’s warm phase — the early inflammatory window where bone metabolism at the injury site is abnormal — is the treatable period, which is why CRPS-RISE restricts enrollment to patients with positive triple-phase bone scans. Enriching for the responsive population raises the trial’s effect size; the trade-off is a narrower label if it works.

Risks and What Could Go Wrong

1. The binary. One Phase 3 trial, p-value in 2028. Enrichment helps, but CRPS trials have a history of placebo-arm improvement that swallows effect sizes — warm-phase enrichment mitigates this without eliminating it.
2. Legacy-holder wipeout risk. At 6.8% of the company, original HOWL investors need the trial to win outright just to recover dilution; partial efficacy is a zero for them.
3. Funding-event gap. Runway to 2029 is adequate for the readout, but any trial extension, expansion, or NDA delay forces a raise into a binary-event window.
4. Founder-driven governance. A Vivek Ramaswamy-chaired structure with activist-entrepreneur DNA can pivot strategy abruptly — an asset for promotion, a risk for holders expecting a straight line to the readout.

Net: a well-funded, regulatorily de-risked single-shot trade with a 2028 fuse. Position sizing is everything — this is lottery-weight, never core.